Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Lucira Health, Inc. (LHDX : NSDQ)
 
 • Company Description   
Lucira Health Inc. is a medical technology company. It is focused on the development and commercialization of transformative and infectious disease test kits. Lucira Health Inc. is based in Emeryville, California.

Number of Employees: 141

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.13 Daily Weekly Monthly
20 Day Moving Average: 102,274 shares
Shares Outstanding: 39.87 (millions)
Market Capitalization: $84.92 (millions)
Beta: 0.62
52 Week High: $11.10
52 Week Low: $1.98
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -30.84% -22.12%
12 Week -53.19% -48.54%
Year To Date -75.26% -69.06%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1412 62ND STREET
-
EMERYVILLE,CA 94608
USA
ph: 510-350-8071
fax: -
None http://www.lucirahealth.com
 
 • General Corporate Information   
Officers
Erik T. Engelson - President; Chief Executive Officer and Director
Daniel George - Chief Financial Officer and Treasurer
Sandra A. Gardiner - Director
David Lamond - Director
Alison McCauley - Director

Peer Information
Lucira Health, Inc. (BJCT)
Lucira Health, Inc. (CADMQ)
Lucira Health, Inc. (APNO)
Lucira Health, Inc. (UPDC)
Lucira Health, Inc. (IMTIQ)
Lucira Health, Inc. (CYGN)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED PRODUCTS
Sector: Medical
CUSIP: 54948U105
SIC: 2835
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/11/22
Share - Related Items
Shares Outstanding: 39.87
Most Recent Split Date: (:1)
Beta: 0.62
Market Capitalization: $84.92 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.30 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $0.44 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 40.24% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/11/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 4.79
Trailing 12 Months: -
PEG Ratio: 0.12
Price Ratios
Price/Book: 0.41
Price/Cash Flow: -
Price / Sales: 0.47
EPS Growth
vs. Year Ago Period: 164.81%
vs. Previous Quarter: 1,266.67%
Sales Growth
vs. Year Ago Period: 1,903.41%
vs. Previous Quarter: 48.02%
ROE
03/31/22 - -10.14
12/31/21 - -22.89
09/30/21 - -43.84
ROA
03/31/22 - -8.05
12/31/21 - -19.84
09/30/21 - -31.34
Current Ratio
03/31/22 - 3.72
12/31/21 - 4.10
09/30/21 - 7.03
Quick Ratio
03/31/22 - -
12/31/21 - 3.09
09/30/21 - 5.46
Operating Margin
03/31/22 - -11.37
12/31/21 - -51.01
09/30/21 - -196.88
Net Margin
03/31/22 - -21.47
12/31/21 - -69.67
09/30/21 - -230.43
Pre-Tax Margin
03/31/22 - -21.32
12/31/21 - -69.65
09/30/21 - -230.43
Book Value
03/31/22 - 5.13
12/31/21 - 4.81
09/30/21 - 5.01
Inventory Turnover
03/31/22 - 2.52
12/31/21 - 2.25
09/30/21 - 1.43
Debt-to-Equity
03/31/22 - 0.14
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 12.42
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©